Funding a smoking cessation program for crohn's disease: An economic evaluation

American Journal of Gastroenterology

Volumn 110, Issue 3, 2015, Pages 368-377

  Coward, Stephanie ^a   Heitman, Steven J ^a   Clement, Fiona ^a   Negron, Maria ^a,b   Panaccione, Remo ^a   Ghosh, Subrata ^a   Barkema, Herman W ^a,b   Seow, Cynthia ^a   Leung, Yvette P Y ^a   Kaplan, Gilaad G ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; INFLIXIMAB; VARENICLINE; BENZAZEPINE DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; NICOTINE GUM; NICOTINIC AGENT; QUINOXALINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; COUNSELING; CROHN DISEASE; DRUG COST; DRUG DOSE ESCALATION; ECONOMIC EVALUATION; FUNDING; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH STATUS; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; NICOTINE REPLACEMENT THERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REMISSION; SENSITIVITY ANALYSIS; SMOKING CESSATION PROGRAM; ANTAGONISTS AND INHIBITORS; CANADA; COST BENEFIT ANALYSIS; DIRECTIVE COUNSELING; ECONOMICS; EVALUATION STUDY; FEMALE; MALE; PATHOPHYSIOLOGY; PROCEDURES; PROGRAM EVALUATION; PSYCHOLOGY; SMOKING; SMOKING CESSATION; STATISTICAL MODEL; UTILIZATION;

ADULT; AZATHIOPRINE; BENZAZEPINES; CANADA; COST-BENEFIT ANALYSIS; CROHN DISEASE; DIRECTIVE COUNSELING; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MODELS, STATISTICAL; NICOTINIC AGONISTS; PROGRAM EVALUATION; QUALITY-ADJUSTED LIFE YEARS; QUINOXALINES; SMOKING; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84924445959     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2014.300     Document Type: Article

References (43)

1. Frolkis AD , Dykeman J , Negron ME et al. Risk of surgery for infl ammatory bowel diseases has decreased over time: A systematic review and metaanalysis of population-based studies . Gastroenterology 2013 ; 145 : 996-1006
2. Molodecky NA , Soon IS , Rabi DM et al. Increasing incidence and prevalence of the infl ammatory bowel diseases with time, based on systematic review . Gastroenterology 2012 ; 142 : 46-54 e42; quiz e30
3. Reese GE , Nanidis T , Borysiewicz C et al. The eff ect of smoking aft er surgery for Crohn's disease: A meta-analysis of observational studies . Intl J Colorectal Dis 2008 ; 23 : 1213-21
4. Sands BE , Arsenault JE , Rosen MJ et al. Risk of early surgery for Crohn's disease: Implications for early treatment strategies . Am J Gastroenterol 2003 ; 98 : 2712-8
5. Cosnes J , Beaugerie L , Carbonnel F et al. Smoking cessation and the course of Crohn's disease: An intervention study . Gastroenterology 2001 ; 120 : 1093-9
6. Calkins BM . A meta-analysis of the role of smoking in infl ammatory bowel disease . Dig Dis Sci 1989 ; 34 : 1841-54
7. Frolkis A , Dieleman LA , Barkema H et al. Environment and the infl ammatory bowel diseases . Can J Gastroenterol 2013 ; 27 : E18-e24
8. Molodecky NA , Kaplan GG . Environmental risk factors for infl ammatory bowel disease . Gastroenterol Hepatol (NY) 2010 ; 6 : 339-46
9. Nunes T , Etchevers MJ , Merino O et al. High smoking cessation rate in Crohn's disease patients aft er physician advice-The TABACROHN Study. J Crohns Colitis 2012 ; 7 : 202-7
10. Nunes T , Etchevers MJ , Merino O et al. High smoking cessation rate in Crohns disease patients attending a multicenter anti-Tobacco program: The TABACROHN Study . Dig Dis Week 2012 : San Diego CA, USA , 2012
11. Rocchi A , Benchimol EI , Bernstein CN et al. Infl ammatory bowel disease: A Canadian burden of illness review . Can J Gastroenterol 2012 ; 26 : 811-7
12. Canadian Agency for Drugs and Technologies in Health . Guidelines for the economic evaluation of health technologies: Canada [3rd Edition]. 2006 http://www.cadth.ca/media/pdf/186-EconomicGuidelines-e.pdf. Accessed 29 January 2014
13. Lancaster T , Stead LF . Individual behavioural counselling for smoking cessation . Cochrane Database Syst Rev 2005 ; 2 : CD001292
14. H ughes JR , Gulliver SB , Fenwick JW et al. Smoking cessation among self-quitters . Health Psychol 1992 ; 11 : 331-4
15. Stead LF , Perera R , Bullen C et al. Nicotine replacement therapy for smoking cessation . Cochrane Database Syst Rev 2012 ; 11 : CD000146
16. Cahill K , Stead LF , Lancaster T . Nicotine receptor partial agonists for smoking cessation . Cochrane Database Syst Rev 2012 ; 4 : CD006103
17. Rutgeerts P , Feagan BG , Lichtenstein GR et al. Comparison of scheduled and episodic treatment strategies of infl iximab in Crohn's disease . Gastroenterology 2004 ; 126 : 402-13
18. Colombel JF , Sandborn WJ , Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial . Gastroenterology 2007 ; 132 : 52-65
19. Gisbert JP , Panes J . Loss of response and requirement of infl iximab dose intensifi cation in Crohn's disease: A review . Am J Gastroenterol 2009 ; 104 : 760-7
20. Billioud V , Sandborn WJ , Peyrin-Biroulet L . Loss of response and need for adalimumab dose intensifi cation in Crohn's disease: A systematic review. Am J Gastroenterol 2011 ; 106 : 674-84
21. Statistics Canada . Age-Standardized mortality rates by selected causes, by sex. 2009 http://www.statcan.gc.ca/tables-Tableaux/sum-som/l01/cst01/health30a-eng.htm . Accessed 10 June 2012
22. Duricova D , Pedersen N , Elkjaer M et al. Overall and cause-specifi c mortality in Crohn's disease: A meta-analysis of population-based studies. Infl amm Bowel Dis 2010 ; 16 : 347-53
23. Narula N , Fedorak RN . Does smoking reduce infl iximab's eff ectiveness against Crohn's disease? Can J Gastroenterol 2009 ; 23 : 121-5
24. Ma C , Panaccione R , Heitman SJ et al. Systematic review: The short-Term and long-Term effi cacy of adalimumab following discontinuation of infl iximab . Aliment Pharmacol Ther 2009 ; 30 : 977-86
25. D'Haens GR , Panaccione R , Higgins PD et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: When to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011 ; 106 : 199-212 , quiz 213
26. Alberta Blue Cross. Alberta Blue Cross Interactive Drug Benefi t List. 2014 https://idbl.ab.bluecross.ca/idbl/load.do . Accessed 19 February 2014
27. Bonafede MM , Gandra SR , Watson C et al. Cost per treated patient for etanercept, adalimumab, and infl iximab across adult indications: A claims analysis . Adv Ther 2012 ; 29 : 234-48
28. Bureau of Labor Statistics . Consumer Price Index (United States of America). 2014 http://www.bls.gov/cpi/ . Accessed 24 February 2014
29. Statistics Canada . Consumer Price Index. 2014 http://www.statcan.gc.ca/tables-Tableaux/sum-som/l01/cst01/econ09a-eng.htm . Accessed 19 February 2014
30. Cohen RD , Larson LR , Roth JM et al. The cost of hospitalization in Crohn's disease . Am J Gastroenterol 2000 ; 95 : 524-30
31. Bernstein CN , Longobardi T , Finlayson G et al. Direct medical cost of managing IBD patients: A Canadian population-based study . Infl amm Bowel Dise 2011 ; 18 : 1498-508
32. Gregor JC , McDonald JWD , Klar N et al. An evaluation of utility measurement in Crohn's disease . Infl amm Bowel Dis 1997 ; 3 : 265-76
33. Burisch J , Pedersen N , Cukovic-Cavka S et al. Environmental factors in a population-based inception cohort of infl ammatory bowel disease patients in Europe-An ECCO-EpiCom study . J Crohns Colitis 2013 ; 8 : 607-16
34. Loft us CG , Loft us EV Jr. , Harmsen WS et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000 . Infl amm Bowel Dis 2007 ; 13 : 254-61
35. United States Census Bureau. U.S. and World Population Clock . http://www.census.gov/popclock/ . Accessed 8 December 2013
36. Nguyen GC , Devlin SM , Afi f W et al. Defi ning quality indicators for bestpractice management of infl ammatory bowel disease in Canada . Can J Gastroenterol Hepatol 2014 ; 28 : 275-85
37. Leung Y , Kaplan GG , Rioux KP et al. Assessment of variables associated with smoking cessation in Crohn's disease . Dig Dis Sci 2012 ; 57 : 1026-32
38. Anthenelli RM , Morris C , Ramey TS et al. Eff ects of varenicline on smoking cessation in adults with stably treated current or past major depression: A randomized trial . Ann Intern Med 2013 ; 159 : 390-400
39. Cahill K , Stevens S , Perera R et al. Pharmacological interventions for smoking cessation: An overview and network meta-analysis . Cochrane Database Syst Rev 2013 ; 5 : CD009329
40. Gibbons RD , Mann JJ . Varenicline, smoking cessation, and neuropsychiatric adverse events . Am J Psychiatry 2013 ; 170 : 1460-7
41. U.S. Food and Drug Administration . Postmarket Drug Safety Information for Patients and Providers (Varenicline). 2014 http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsand Providers/ucm124818.htm . Accessed 24 May 2014
42. Alberta Health Services . Alberta Health Services Job Board. 2014 http://www.albertahealthservices.ca/careers/ . Accessed 19 February 2014
43. Alberta Health Services . Addiction Centre. 2012 www.addictioncentre.ca. Accessed 6 June 2012